Visser Renée M, Kunze Anna E, Westhoff Bianca, Scholte H Steven, Kindt Merel
Department of Psychology, University of Amsterdam, 1018 XA Amsterdam, The Netherlands; Amsterdam Brain and Cognition (ABC), University of Amsterdam, 1018 VZ Amsterdam, The Netherlands.
Department of Psychology, University of Amsterdam, 1018 XA Amsterdam, The Netherlands.
Psychoneuroendocrinology. 2015 May;55:8-20. doi: 10.1016/j.psyneuen.2015.01.021. Epub 2015 Feb 3.
Neuroimaging research on emotional memory has greatly advanced our understanding of the pathogenesis of anxiety disorders. While the behavioral expression of fear at the time of encoding does not predict whether an aversive experience will evolve into long-term fear memory, the application of multi-voxel pattern analysis (MVPA) for the analysis of BOLD-MRI data has recently provided a unique marker for memory formation. Here, we aimed to further investigate the utility of this marker by modulating the strength of fear memory with an α2-adrenoceptor antagonist (yohimbine HCl). Fifty-two healthy participants were randomly assigned to two conditions - either receiving 20mg yohimbine or a placebo pill (double-blind) - prior to differential fear conditioning and MRI-scanning. We examined the strength of fear associations during acquisition and retention of fear (48 h later) by assessing the similarity of BOLD-MRI patterns and pupil dilation responses. Additionally, participants returned for a follow-up test outside the scanner (2-4 weeks), during which we assessed fear-potentiated startle responses. Replicating our previous findings, neural pattern similarity reflected the development of fear associations over time, and unlike average activation or pupil dilation, predicted the later expression of fear memory (pupil dilation 48 h later). While no effect of yohimbine was observed on markers of autonomic arousal, including salivary α-amylase (sAA), we obtained indirect evidence for the noradrenergic enhancement of fear memory consolidation: sAA levels showed a strong increase prior to fMRI scanning, irrespective of whether participants had received yohimbine, and this increase correlated with the subsequent expression of fear (48 h later). Remarkably, this noradrenergic enhancement of fear was associated with changes in neural response patterns at the time of learning. These findings provide further evidence that representational similarity analysis is a sensitive tool for studying (enhanced) memory formation.
关于情绪记忆的神经影像学研究极大地推动了我们对焦虑症发病机制的理解。虽然编码时恐惧的行为表现并不能预测厌恶经历是否会演变成长期恐惧记忆,但多体素模式分析(MVPA)在分析血氧水平依赖性功能磁共振成像(BOLD-MRI)数据中的应用,最近为记忆形成提供了一个独特的标记物。在此,我们旨在通过用α2肾上腺素能受体拮抗剂(盐酸育亨宾)调节恐惧记忆的强度,进一步研究该标记物的效用。52名健康参与者在进行差异恐惧条件反射和MRI扫描之前,被随机分配到两种情况——要么服用20mg盐酸育亨宾,要么服用安慰剂药丸(双盲)。我们通过评估BOLD-MRI模式和瞳孔扩张反应的相似性,来检测恐惧习得和保持(48小时后)期间恐惧关联的强度。此外,参与者在扫描仪外进行了一次随访测试(2-4周),在此期间我们评估了恐惧增强的惊吓反应。重复我们之前的研究结果,神经模式相似性反映了恐惧关联随时间的发展,并且与平均激活或瞳孔扩张不同,它预测了后期恐惧记忆的表达(瞳孔扩张48小时后)。虽然未观察到盐酸育亨宾对包括唾液α淀粉酶(sAA)在内的自主唤醒标记物有影响,但我们获得了去甲肾上腺素能增强恐惧记忆巩固的间接证据:无论参与者是否服用了盐酸育亨宾,在功能磁共振成像扫描前sAA水平均显著升高,且这种升高与随后的恐惧表达(48小时后)相关。值得注意的是,这种去甲肾上腺素能对恐惧的增强与学习时神经反应模式的变化有关。这些发现进一步证明,表征相似性分析是研究(增强的)记忆形成的一种灵敏工具。